- Home
- SCLX vs ANL Comparison
SCLX vs ANL Comparison
Compare SCLX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- ANL
- Stock Information
- Founded
- SCLX 2011
- ANL 2004
- Country
- SCLX United States
- ANL Cayman Islands
- Employees
- SCLX N/A
- ANL N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- SCLX Health Care
- ANL
- Exchange
- SCLX Nasdaq
- ANL Nasdaq
- Market Cap
- SCLX 72.5M
- ANL 79.0M
- IPO Year
- SCLX N/A
- ANL 2023
- Fundamental
- Price
- SCLX $0.45
- ANL $2.05
- Analyst Decision
- SCLX Strong Buy
- ANL Strong Buy
- Analyst Count
- SCLX 3
- ANL 2
- Target Price
- SCLX $11.33
- ANL $9.00
- AVG Volume (30 Days)
- SCLX 184.3K
- ANL 13.8K
- Earning Date
- SCLX 03-11-2025
- ANL 02-24-2025
- Dividend Yield
- SCLX N/A
- ANL N/A
- EPS Growth
- SCLX N/A
- ANL N/A
- EPS
- SCLX N/A
- ANL N/A
- Revenue
- SCLX $55,152,000.00
- ANL $5,000,000.00
- Revenue This Year
- SCLX $32.77
- ANL N/A
- Revenue Next Year
- SCLX $50.71
- ANL N/A
- P/E Ratio
- SCLX N/A
- ANL N/A
- Revenue Growth
- SCLX 9.41
- ANL N/A
- 52 Week Low
- SCLX $0.38
- ANL $1.85
- 52 Week High
- SCLX $2.63
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- SCLX 42.08
- ANL 44.92
- Support Level
- SCLX $0.40
- ANL $2.00
- Resistance Level
- SCLX $0.53
- ANL $2.19
- Average True Range (ATR)
- SCLX 0.05
- ANL 0.27
- MACD
- SCLX 0.01
- ANL -0.01
- Stochastic Oscillator
- SCLX 47.59
- ANL 16.81
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.